4E40 Stock Chart & Stats
€0.20
€2.84(70.70%)
At close: 4:00 PM EST
€0.20
€2.84(70.70%)
Day’s Range― - ―
52-Week Range€0.14 - €47.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.73M
Enterprise Value€16.37M
Total Cash (Recent Filing)€8.19M
Total Debt (Recent Filing)€10.69M
Price to Earnings (P/E)―
Beta-3.01
Next Earnings
Nov 12, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-46.25
Shares Outstanding1,642,565
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio-5.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.46Price Target Upside16632.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.68
Revenue Forecast (FY)€4.57M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong trailing-twelve-month revenue growth indicates that Scienture is expanding commercial activity and gaining product-level traction. If sustained, this larger revenue base can improve operating leverage and create a foundation for narrowing losses as the portfolio matures.
Commercial Portfolio ExpansionThe addition of Rezenopy to the commercial-stage portfolio, alongside continuing Arbli traction, broadens Scienture’s potential revenue base. More launched products and expanding distribution channels could support durable growth and reduce reliance on a single commercial product.
Moderate Current LeverageCurrent leverage appears moderate relative to the company’s equity base, which provides more balance-sheet capacity than a highly debt-funded structure. This may preserve flexibility to support commercialization and development while limiting the immediate burden of debt service.
Bears Say
Persistent Operating LossesScienture’s substantial net, EBIT, and EBITDA losses show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can constrain reinvestment, require additional capital, and make profitability dependent on successful execution and significant cost improvement.
Severe Cash BurnDeeply negative operating and free cash flow indicate that the business is consuming cash rather than funding operations internally. Persistent cash burn increases ongoing financing needs and leaves less financial flexibility to commercialize products or absorb execution setbacks.
Balance-Sheet InstabilityAlthough current leverage is moderate, the historical swings in debt-to-equity and equity levels reduce confidence in the stability of Scienture’s capital structure. Such variability can complicate planning and may increase dependence on future financing decisions as the company scales.
Scienture Holdings News
4E40 FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was €0.14 and its highest was €47.50 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is €5.73M.
When is Scienture Holdings’s upcoming earnings report date?
Scienture Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 29 days.
How were Scienture Holdings’s earnings last quarter?
Scienture Holdings released its earnings results on Aug 14, 2026. The company reported -€1.562 earnings per share for the quarter, beating the consensus estimate of -€2.008 by €0.446.
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings does not currently pay dividends.
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate is -1.34.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 1,642,565 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Scienture Holdings reported an EPS of -€1.562 in its last earnings report, beating expectations of -€2.008. Following the earnings report the stock price went up 5.968%.
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in DE:4E40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
4E40 Stock 12 Month Forecast
Average Price Target
€33.46
▲(16632.12% Upside)